.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Farmers Insurance
Covington
Cerilliant
Moodys
McKinsey
Harvard Business School
Queensland Health
Dow
Federal Trade Commission

Generated: November 18, 2017

DrugPatentWatch Database Preview

SPINRAZA Drug Profile

« Back to Dashboard

What is the patent landscape for Spinraza, and when can generic versions of Spinraza launch?

Spinraza is a drug marketed by Biogen Idec and is included in one NDA. There are eight patents protecting this drug.

This drug has five hundred and fifty-four patent family members in twenty-five countries.

The generic ingredient in SPINRAZA is nusinersen sodium. One supplier is listed for this compound. Additional details are available on the nusinersen sodium profile page.

Summary for SPINRAZA

US Patents:8
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Drug Prices:see details
DailyMed Link:SPINRAZA at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Biogen Idec
SPINRAZA
nusinersen sodium
SOLUTION;INTRATHECAL209531-001Dec 23, 2016RXYesYes► Subscribe► Subscribe ► Subscribe
Biogen Idec
SPINRAZA
nusinersen sodium
SOLUTION;INTRATHECAL209531-001Dec 23, 2016RXYesYes► Subscribe► SubscribeYY ► Subscribe
Biogen Idec
SPINRAZA
nusinersen sodium
SOLUTION;INTRATHECAL209531-001Dec 23, 2016RXYesYes► Subscribe► Subscribe► Subscribe
Biogen Idec
SPINRAZA
nusinersen sodium
SOLUTION;INTRATHECAL209531-001Dec 23, 2016RXYesYes► Subscribe► Subscribe ► Subscribe
Biogen Idec
SPINRAZA
nusinersen sodium
SOLUTION;INTRATHECAL209531-001Dec 23, 2016RXYesYes► Subscribe► Subscribe ► Subscribe
Biogen Idec
SPINRAZA
nusinersen sodium
SOLUTION;INTRATHECAL209531-001Dec 23, 2016RXYesYes► Subscribe► Subscribe ► Subscribe
Biogen Idec
SPINRAZA
nusinersen sodium
SOLUTION;INTRATHECAL209531-001Dec 23, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
Biogen Idec
SPINRAZA
nusinersen sodium
SOLUTION;INTRATHECAL209531-001Dec 23, 2016RXYesYes► Subscribe► Subscribe► Subscribe
Biogen Idec
SPINRAZA
nusinersen sodium
SOLUTION;INTRATHECAL209531-001Dec 23, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
Biogen Idec
SPINRAZA
nusinersen sodium
SOLUTION;INTRATHECAL209531-001Dec 23, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: SPINRAZA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,148,204Antisense modulation of bcl-x expression► Subscribe
5,760,202 Process for the synthesis of 2'-O-substituted pyrimidines► Subscribe
6,642,367 Process for the synthesis of 2'-O-substituted pyrimidines and oligomeric compounds therefrom► Subscribe
8,946,183Compositions and methods for modulation of SMN2 splicing► Subscribe
6,214,986 Antisense modulation of bcl-x expression► Subscribe
6,222,025 Process for the synthesis of 2'-O-substituted pyrimidines and oligomeric compounds therefrom► Subscribe
8,586,559Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences► Subscribe
9,107,933Compositions and methods of targeting apolipoprotein B for the reduction of apolipoprotein C-III► Subscribe
5,861,493 Process for the synthesis of 2'-O-substituted pyrimidines► Subscribe
6,172,216 Antisense modulation of BCL-X expression► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: SPINRAZA

Country Document Number Estimated Expiration
Japan2580091► Subscribe
European Patent Office1448762► Subscribe
European Patent Office2548560► Subscribe
HungaryT63430► Subscribe
Spain2138972► Subscribe
European Patent Office0975654► Subscribe
Greece3024873► Subscribe
Hungary9402657► Subscribe
Australia4383093► Subscribe
Australia6952800► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Farmers Insurance
Federal Trade Commission
Johnson and Johnson
Dow
Julphar
Cipla
Deloitte
Chubb
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot